Medtronic plc (MDT) is Closing in on Dividend King Status

Medtronic plc (MDT) is on the verge of achieving Dividend King status, having increased its dividend for 49 consecutive years. In June 2026, the company raised its quarterly dividend to $0.72 per share, resulting in an annual payout of $2.88. At a share price around $91, this yields approximately 3.2%. For a large healthcare company with such an impressive dividend history, this represents a solid income return.

Investors are drawn to Medtronic's ability to raise its payout even during challenging economic times and periods of slower growth. The latest 1.4% increase demonstrates the company's commitment to maintaining reliable income for shareholders. However, the focus isn't on rapid dividend growth but rather on the consistency of the payout.

Medtronic's robust cash flow is a key component of its dividend story. In fiscal 2026, the company generated $7.33 billion in operating cash flow, a 4.1% increase from the prior year. Free cash flow reached $5.43 billion, up 4.6%. With $3.64 billion paid in dividends, the company maintained ample cash for other priorities, including capital spending, acquisitions, debt reduction, and share buybacks.

Medtronic ended fiscal 2026 with $9.2 billion in cash and investments. The company does carry debt, but its consistent cash generation provides flexibility to support the dividend while funding business operations. A key indicator of Medtronic's dividend potential is its underlying business performance. Revenue rose 8.4% to $36.4 billion in fiscal 2026, marking the company's strongest annual revenue growth in a decade.

Organic revenue grew by 5.8%. Several newer businesses, including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS, are expected to become significant contributors in the future. Revenue from Cardiac Ablation Solutions surged 78% globally in the fourth quarter, with US revenue increasing 124%. This growth bodes well for dividend investors, as stronger revenue can lead to higher earnings and free cash flow.

Management expects organic revenue growth of 6.75% to 7.25% and adjusted EPS of $5.90 to $6.00 in fiscal 2027, representing growth of 6.7% to 8.5%. This puts the payout ratio at around 48% to 49%, leaving room for continued dividend increases while retaining cash for business investments. Medtronic's dividend case is growing increasingly compelling.

With 49 years of dividend increases under its belt and a strong cash flow position, the company is now just one increase away from becoming a Dividend King. The company's recent results indicate an improving business, with revenue growth accelerating, new medical technologies gaining traction, and management projecting mid- to high-single-digit earnings growth for fiscal 2027.

For dividend investors, Medtronic offers a combination of a well-established healthcare business, a 3% yield, dependable cash flow, and a dividend record nearing 50 consecutive years. While the dividend growth may not be rapid, the yield, long history, and strong cash flow provide a solid foundation for long-term income investors.

Medtronic is positioned as a promising long-term income investment, with the potential for sustained dividend growth as the business continues to evolve and expand.